ClinicalTrials.gg
CompletedNCT03460431Updated Mar 9, 2018

A Study Using Fractional Carbon Dioxide and Long Pulsed Neodymium-yttrium Aluminum Garnet Lasers in Treatment of Keloids

An interventional study of fractional CO2 laser 10,600nm and Nd YAG laser1064 nm in Keloid, sponsored by Cairo University. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-03-09.

Sponsored by Cairo University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 6 months after the study started (first participant enrolled Jul 2014, registered Jan 2018).
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

clinical comparative study comparing the effectiveness of fractional CO2, long pulsed Nd YAG and their combination in collagen remodeling in keloid clinically, biochemically and histopathologically

Read the detailed description

Patients The study included 30 Egyptian patients with keloid scar recruited from the Out Patient Clinic, Dermatology Department, Cairo University.

Methodology

Patients:

  • Thirty patients with keloid scar(s) were included in the study
  • Every patient was subjected to the following:
  1. Complete history taking: History of disease onset, course and duration, family history as well as history of any systemic or dermatological disease interfering with the eligibility of participation in the study.

    Thirty patients were included in the study which is a clinical comparative study comparing the effectiveness of fractional CO2, long pulsed Nd YAG and their combination in collagen remodeling in keloid clinically in all the included patients and biochemically and immunohistochemically fifteen patient

  2. Full clinical examination:

    • General examination to determine any systemic or dermatological disease that might preclude the patient from participation in the study such as collagen disease.
    • Local examination to determine Fitzpatrick skin color of the patient and the site and extent of the scar to be treated.

    Methods:

    • Cases with multiple keloid scars three lesions 2 to 3 cm apart from each other were selected and labeled. The first one (lesion A) was treated using fractional CO2 laser 10,600 nm, the second (lesion B) long pulsed Nd YAG laser 1064 nm, while the last (lesion C) combined fractional CO2 followed by Nd YAG lasers after half an hour were used
    • patients who had a large sized lesion, the lesion was divided into three equal parts 2 to 3 cm apart from each other, they were labeled as areas A, B and C then subjected to the same treatment modalities as mentioned in case of multiple lesions.
    • Patients received 4 treatment sessions 4 to 8 weeks apart. Laser modalities and parameters
    • Topical anesthesia (lidocaine 2.5% and prilocaine 2.5%) was applied to the working area 30 to 60 minutes before the sessions, washed off and properly dried before the procedure.
    • Ablative fractional 10,600 nm carbon dioxide laser (DEKA smartxide DOT, Italy) and long pulsed Nd-YAG (DEKA synchro FT) were used in the treatment sessions with the following parameters Fractional CO2 Stacking: 5, Power: 20 Watt, Dwell time: 1000 micro second, Spacing : 800 micro meter fluence: 40 j/cm2 Pulse duration: 0.3 milli second Spot size: 5 mm Passes: 3.

    Assessment Assessment was done before treatment every session and one months after the final laser treatment. Clinical assessment was done for all patients while histopathological and biochemical assessment were done only in 15 patients.

    A. Clinical evaluation Clinical assessment was fulfilled via calculating the scores of both the Vancouver Scar Scale; and the Patient and Observer Scar Assessment Scale. Patients were assessed every session, any side effects were reported, e.g pain, swelling, infection, hyper pigmentation or hypo pigmentation.

    B. Histopathological and biochemical evaluation

    Fifteen patients were randomly selected and subjected to the pre and post treatment biopsies :

    • Pretreatment biopsy:

    Three mm punch skin biopsy was taken from the keloid (any lesion A, B, or C) before starting treatment sessions ●Post treatment biopsies: Each lesion (A, B, C) was biopsied separately (3 mm punch biopsy), one month after last treatment session.

    Biopsies of controls ●parts of excess skin from 12 patients undergoing abdominoplasty were used as controls for levels of TGFβ1 and TGFβ3.

    Procedure

    • Biopsies were fixed in 10 % neutral buffered formalin, and then embedded in paraffin blocks. Sections were prepared for routine staining by H\&E. Other sections were prepared for histochemical staining of collagen fibres using Masson's trichrome stain and elastic fibres using orcein stain
    • All sections were examined using a Zeiss, Primo star light microscope (Zeiss, Germany). The microscope has an integrated camera by which photomicrographs depicting the various histopathological and histochemical findings were obtained. All photomicrographs presented in the thesis are according to their original magnification.
    • Evaluation of elastic fibres in orcein stained sections:

    Orcein stained sections were graded according to the grading criteria proved by Ozog et al. in 2013 for the appearance of the dermal elastic tissue as follows:

0 normal

  1. short fragmented elastic fibres
  2. intermediate between 1 and 3
  3. fibrillar elastic fibres, parallel to epidermis
  4. intermediate between 3 and 5
  5. absent or nearly absent.

Image analyzer evaluation (morphometric study):

The area percent of collagen and elastic fibres were quantitatively evaluated in Masson's trichrome and orcein stained sections respectively at magnification X100 in 5 non overlapping fields for all patients. Image analysis was done using Leica Qwin 500C image analyzer computer system (England) present in the Histology Department, Faculty of Medicine, Cairo University .

02

Conditions studied

  • Keloid

Browse trials for

03

In context

Keloid

138 studies on the registry are indexed under Keloid; 26 are open to participants now.

This study's enrollment of 30 is close to the median of 30 across 109 interventional studies indexed under Keloid.

Browse Keloid studies →

Lead sponsor

Cairo University is the lead sponsor of 4,941 studies on the registry; 1,458 are open to participants now.

Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with keloid scars of at least 6 months duration.
  • No limitations regarding sex of the patients.
  • Patients with three or more lesions 2 to 3 cm apart or patients having a large sized lesion.

Exclusion criteria

Exclusion Criteria:

  • Patients who had received any form of treatment during the last four weeks prior to treatment such as intralesional or a laser procedure during the last six months.
  • Patients with active skin infections e.g. herpes or disease.
  • Patients with previous history of adverse outcome related to laser therapy.
  • Recent use of Isotretinoin (within 6 months prior to the procedure).
  • Patients with known allergies to lidocaine.
  • Smoking, pregnancy
  • Patients with unrealistic expectations
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    fractional CO2 laser 10,600nm

    fractional CO2 laser 10,600nm one session every month for 4 months

    Device: fractional CO2 laser 10,600nm

  • Experimental
    Nd YAG laser 1064nm

    Nd YAG laser 1064nm

    Device: Nd YAG laser1064 nm

  • Experimental
    combined two laser types

    combined fractional CO2 laser 10,600nm and Nd YAG laser 1064nm lasers treatment to keloid

    Device: fractional CO2 laser 10,600nm · Device: Nd YAG laser1064 nm

Interventions

  • Devicefractional CO2 laser 10,600nm

    fractional CO2 laser 10,600nm session, every month for 4 months

  • DeviceNd YAG laser1064 nm

    Nd YAG laser1064 nm laser session, every month for 4 months

06

What researchers measure

Primary outcomes

  1. comparison between different laser modalities in treatment of keloids clinically

    assessed by Patient and Observer Scar assessment Scale

    Time frame: 5 months

  2. comparison between different laser modalities in treatment of keloids morphometrically

    assessed by Quantitative morphometric analysis using Leica Qwin 500 Image Analyzer (LEICA Imaging Systems Ltd, Cambridge, England) measuring area percent of collagen and elastin fibers in micrometer squared

    Time frame: 5 months

  3. comparison between different laser modalities in treatment of keloids biochemically

    assessed by level of transforming growth factor beta 1 and 3 using Human TGF-B ELISA kit provided by ID labs Biotechnology London, ON, Canada.measurement unit is nano gram per gram tissue

    Time frame: 5 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 9, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03460431
Lead sponsor
Cairo University
Responsible party
Ahmed Foad Mohamed (specialist of dermatology.students hospital. Cairo university, Cairo University) — Principal investigator
First posted
Mar 9, 2018
Start date
Jul 1, 2014
Primary completion
Feb 27, 2017
Completion
Jun 30, 2017
Last update
Mar 9, 2018

Study contacts

Shereen O Tawfik, MD
study director · professor of Dermatology.faculty of medicine. Cairo university

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion